Printer-friendly versionPDF versionSend to friend

Megan Holmes


Admin unit: 
Job title: 
Professor of Molecular Neuroendocrinology
Contact email:
242 6737
47 Little France Crescent



Glucocorticoids have many actions within the body, but it is their actions within the brain and the how the brain controls glucocorticoid release that has been the main focus of my research. It is crucial to tightly regulate glucocorticoid levels to prevent hyperglycemia, insulin resistance, obesity, hypertension, metabolic syndrome, and mood disorders such as depression.

Early-life programming and 11ß-HSD2

The glucocorticoid metabolising enzyme, 11ß-HSD2, converts active cortisol/corticosterone to inactive cortisone/11-dehydrocortisosterone. It is highly expressed in the placenta where it is hypothesized to protect the developing fetus from high levels of glucocorticoids which will alter cell proliferation, differentiation and developmental timings. This will generate long-term consequences on the offspring, making them more susceptible to diseases in later life, such as metabolic syndrome, hypertension and mood disorders.

Consistent with this hypothesis, mice lacking 11ß-HSD2 are born smaller, have delayed postnatal development and exhibit abnormal anxiety behaviour as adults (have decreased entries into more anxiogenic open arm of the Elevated –plus maze). Furthermore, placentas from HSD2-/- mice are smaller, are less vascularized and are dysfunctional, delivering less nutrients to the fetus. Hence, a novel hypothesis is that HSD2 is there to protect the placenta rather than the fetus from high maternal glucocorticoids.

So the question is: Which is the most important site of HSD2 protection against adverse prenatal glucocorticoid programming – the placenta or the fetus? Or both?  To answer this question, we have generated brain-specific and placental-specific HSD2 knockout mice.This will enable us to determine the role of HSD2 in cardio-metabolic programming as well as programming of behaviour.

Early life challenges and life-long risk

Early-life challenges have been implicated in many diseases including cardio-metabolic and psychiatric diseases, such as schizophrenia and depression. Furthermore, the life-long allostatic load will tip the system from healthy ageing into dementias. In our studies we are investigating the interaction of glucocorticoid environment with genetic susceptibility and development to understand the mechanisms causal to adverse ageing. 

Alongside the measurement of physiological parameters (eg blood pressure, metabolism), behavioural assessments (cognitive and mood) and gene expression, we are using imaging paradigms to determine  longitudinal changes, particularly in the brain that may underpin the adverse outcomes.

We (in collaboration with Ian Marshall, Jeremy Hall and others) have set up conscious rat fMRI to study network activation in respose to a learnt fear conditioned cue. This enables us to assess the extent and pattern of activation while the rat is carrying out a simple cognitive task. We can then asess any modulations of this activation in response to early-life challenges and drug treatments.






I run my own research group withing the CVS, am a member of the CVS senior advisory board, and member of the Seminar and symposium committee of the CVS. I am a Fellow of the Society for Biology, a member of Faculty F1000 Biology. I am treasurer of the British Society for Neuroendocrinolgy. I am Associate Editor of Stress and am on the Editorial Board of the Journal of Neuroendocrinology.

Research images: 
BOLD Activation in Lateral Amygdala in response to Conditioned stimulus